Interestingly, it was recently shown that treatment with liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue, also reduces hepatic steatosis and can even lead to histological resolution of non-alcoholic steatohepatitis (NASH)8. This evidence concerns the gene GLP1R and fatty liver disease.